Cetuximab Archives - Medical Conferences

CAPRI 2 GOIM trial navigates biomarker-driven therapy

Presented By

Dr Giulia Martini, University of Campania Luigi Vanvitelli, Italy

Trial

Phase 2, CAPRI 2 GOIM

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:44

Meta-analysis of triplet therapy in BRAFV600E-mutated mCRC

Presented By

Dr Davi Said G. Celso, Federal University of Viçosa, Brazil

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:41

Clinical biomarkers may guide therapy selection in RAS wildtype mCRC

Presented By

Dr Julian Holch, Ludwig-Maximilians-University of Munich, Germany

Trial

Phase 3, FIRE-3 (AIO KRK0306)

Conference

ASCO GI 2024

Type

News article

13 February 2024 12:31

Adagrasib shows promising clinical activity in heavily pretreated KRAS-mutated CRC

Presented By

Dr Jared Weiss, University of North Carolina at Chapel Hill, NC, USA

Trial

Phase 1/2, KRYSTAL-1

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:42

Maintenance treatment with cetuximab versus observation in RAS wildtype mCRC

Presented By

Dr Valérie Boige, Institut Gustave Roussy, France

Trial

Phase 2, PRODIGE 28-time UNICANCER

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:33

Rechallenge of RAS/BRAF wildtype CRC with avelumab plus cetuximab

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:13

Advanced colorectal cancer and BRAF mutations: triplet combination improves survival

Presented By

Prof. Scott Kopetz, MD Anderson Cancer Center, Houston, USA

Trial

Phase 3, BEACON CRC

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 14:22